Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $122.70

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $122.70.

Several analysts have commented on the stock. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler lowered their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently added to or reduced their stakes in the stock. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group in the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group in the 4th quarter worth approximately $33,000. Sachetta LLC bought a new stake in TransMedics Group in the 4th quarter worth approximately $40,000. AlphaQuest LLC bought a new stake in TransMedics Group in the 4th quarter worth approximately $52,000. Finally, Quarry LP grew its position in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $67.65 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a one year low of $55.00 and a one year high of $177.37. The company has a 50-day simple moving average of $68.55 and a two-hundred day simple moving average of $95.67. The firm has a market capitalization of $2.28 billion, a PE ratio of 71.97 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.